Bi-aryl or aryl-heteroaryl substituted indoles

Details Bi-aryl or aryl-heteroaryl substituted indoles Bi-aryl or aryl-heteroaryl substituted indoles

2007-05-25

2010-06-22

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S418000, C548S467000, C548S484000

Reexamination Certificate

active

07741360

ABSTRACT:
The present invention relates to substituted indoles of Formula (I) useful as pharmaceutical compounds for treating respiratory disorders.

REFERENCES:
patent: 5459150 (1995-10-01), Brooks et al.
patent: 5486525 (1996-01-01), Summers, Jr. et al.
patent: 5567711 (1996-10-01), Sheppard et al.
patent: 6916841 (2005-07-01), Seehra et al.
patent: 6933316 (2005-08-01), Hsieh et al.
patent: 7166607 (2007-01-01), Bonnert et al.
patent: 2005/0222201 (2005-10-01), Birkinshaw et al.
patent: 2006/0111426 (2006-05-01), Bonnert et al.
patent: 2006/0264444 (2006-11-01), Bonnert et al.
patent: 2008/0027092 (2008-01-01), Bonnert et al.
patent: 2008/0051586 (2008-02-01), Keegan et al.
patent: 2008/0249110 (2008-10-01), Bonnert et al.
patent: 2009/0143449 (2009-06-01), Bonnert et al.
patent: 0254241 (1988-01-01), None
patent: 0530907 (1993-03-01), None
patent: 0576347 (1993-12-01), None
patent: 0 924 209 (1999-06-01), None
patent: 1170594 (2002-01-01), None
patent: 1505061 (2005-02-01), None
patent: 1356834 (1974-06-01), None
patent: 2422831 (2006-08-01), None
patent: WO 94/19321 (1994-09-01), None
patent: WO 95/16687 (1995-06-01), None
patent: WO 98/13368 (1998-04-01), None
patent: WO 99/09007 (1999-02-01), None
patent: WO 00/78761 (2000-12-01), None
patent: WO 01/032621 (2001-05-01), None
patent: WO 01/47922 (2001-07-01), None
patent: WO 01/92224 (2001-12-01), None
patent: WO 03/064387 (2003-08-01), None
patent: WO 03/066046 (2003-08-01), None
patent: WO 03/066047 (2003-08-01), None
patent: WO 03/097598 (2003-11-01), None
patent: WO 03/101961 (2003-12-01), None
patent: WO 03/101981 (2003-12-01), None
patent: WO 2004/007451 (2004-01-01), None
patent: WO 2004/016609 (2004-02-01), None
patent: WO 2004/106302 (2004-12-01), None
patent: WO 2005/019171 (2005-03-01), None
patent: WO 2005/040114 (2005-05-01), None
patent: WO 2005/054232 (2005-06-01), None
patent: WO 2006/075139 (2006-07-01), None
patent: WO 2007/138282 (2007-12-01), None
patent: WO 2007/140786 (2007-12-01), None
patent: WO 2008/000409 (2008-01-01), None
Antonio R. Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thedition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL: http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indez.html, pp. 1 and 2.
“COPD: Causes and Prevention.” NIH SeniorHealth. National Heart, Lung, and Blood Institute. Accessed Apr. 6, 2009. <http:/
ihseniorhealth.gov/copd/causesandprevention/01.html>.
“Prevention of Cystic Fibrosis.” WrongDiagnosis.com. Accessed Apr. 6, 2009. <http://www.wrongdiagnosis.com/c/cf/prevent.htm>.
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
STN International, CAPLUS accession No. 2001:338492, Document No. 134:353315, Wakunaga Pharmaceutical Co., Ltd., “Preparation of indole derivatives as chymase inhibitors and drugs containing the same as the active ingredient”, & WO,A1,2001032621, 20010510, RN 64137-76-4, 336186-33-5.
STN International, CHEMCATS accession No. 2000:1027702, Apr. 26, 2001, 8004-3013, “1H-Indole-1-acetic acid, 2-methyl-3-(phenylthio)-, ethyl esther”, CAS Registry No. 300860-50-8.
STN International, file CAPLUS, CAPUS accession No. 1995:401159, Document No. 122:187576, Yoshitomi Pharmaceutical Industries, Ltd., “Preparation of fused pyrazole derivatives”, & JP,A2, 06206872, 19940726.
Vippagunta et al., abstract, “Crystalline solids”,Advanced Drug Delivery Reviews48:3-26 (2001).
Atkinson et al., “A New Synthesis of 3-Arylthioindoles”,Synthesis6:480-481 (1988).
Cecil Textbook of Medicine, 20th edition, vol. 2:1992-1996 (1996).
Cecil Textbook of Medicine, 20thedition, vol. 2:2050-2057 (1996).
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL:http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indexhtml>.
Database CA ′Online! Chemical Abstracts Service, Columbus, Ohio, US; Tanimoto, Norihiko et al: “Preparation of indole derivatives as PGD2 receptor antagonists” XP002301963 retrieved from STN Database accession No. 2003:931327.
Garcia et al., “A Novel Synthesis of 3-Cyanoindoles and a New Route to Indole-3-Carboxylic Acid Derivatives”,Tetrahedron Letters26(15):1827-1830 (1985).
Hamel et al., “Regioselective Synthesis of Mixed Indole 2,3-Bis(sulfides). A Study of the Mechanism of the Second Sulfenylation of Indole”,J. Org. Chem. 61:1573-1577 (1996).
Hary et al., “Efficient synthesis of 3-(4,5-dihydro-1H-imidazole-2-y1)-1H-indoles”,Tetrahedron Letters42:5187-5189 (2001).
Howard et al., “Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone-and oxindole-1-acetic acids”,Eur J Med Chem27:779-789 (1992).
Lüscher et al., “Deblocking ofo-Nitrophenylsulfenyl-Protected Peptides by Ammonium Thiocyanate and (2-Methyl-1-indolyl) acetic acid”,Helv. Chim. Acta66(2):602-605 (1983).
Matassa et al., “Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles”,J. Med. Chem.33:1781-1790 (1990).
Matsugi et al., “An efficient sylfenylation of aromatics using highly active quinone monoO,S-acetal bearing a pentafluorophenylthio group”,Tetrahedron Letters42:1077-1080 (2001).
Matsugi et al., “Facile and Efficient Sulfenylation Method Using Quinone Mono-O,S-Acetals under Mild Conditions”,J. Org. Chem.66:2434-2441 (2001).
Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids”,Advanced Drug Delivery Reviews56:275-300 (2004).
Ovenden et al., “Echinosulfonic Acids A-C and Echinosulfone A: Novel Bromoindole Sulfonic Acids and a Sulfone from a Southern Australian Marine Sponge,Echinodictyum”, J. Nat. Prod. 62:1246-1249 (1999).
Patani and LaVoie, “Bioisosterism: A Rational Approach in Drug Design”,Chem Rev.96:3147-3176 (1996).
STN International, CAPLUS accession No. 1977:535057, Document No. 87:135057, Sankyo Co., Ltd., “3- Indolyl thio ethers”, & JP,A2,52039671, 19770328, RN 64137-76-4, 54491-43-9, 56366-45-1.
STN International, CAPLUS accession No. 1980:6356, Document No. 92:6356, Gabrielyan, G.E. et al.: “Indole derivatives. LX. Synthesis of indole compounds with a furan ring”, & Armyanskii Khimicheskii Zhurnal (1979), 32(4), 309-14, RN 51842-57-0.
STN International, CAPLUS accession No. 2001:235566, Document No. 134:266203, Kato, Susumu et al.: “Preparation and application of benzopyranone derivatives”; & JP,A2,2001089471, 20010403, RN 332082-10-7.

Affiliated with

Also associated with

Rating

Bi-aryl or aryl-heteroaryl substituted indoles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bi-aryl or aryl-heteroaryl substituted indoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bi-aryl or aryl-heteroaryl substituted indoles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4175992